Angiotensin receptor blockers are a well-studied class of therapeutics that could provide an additional benefit to MPS I patients by inhibiting TGF-β signaling through pERK1/2 as they have been shown to do in Marfan syndrome [22,27,30,31]. Here, TGFB1 is linked to Scheie syndrome.